Extension Study of ASP015K - Open-Label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase IIb Study or Phase III Study of ASP015K.

Trial Profile

Extension Study of ASP015K - Open-Label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase IIb Study or Phase III Study of ASP015K.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Peficitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Apr 2017 Planned End Date changed from 1 Sep 2018 to 30 Sep 2018.
    • 19 Apr 2017 Planned primary completion date changed from 1 Sep 2018 to 30 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top